Combination therapy with PDE3A inhibitor anagrelide and idarubicin has shown synergistic anti-leukemic effects through caspase-3-GSDME-mediated pyroptosis in PDE3A-high AML [182]. Here, PDE3A is linked to acute myeloid leukemia.